Extensively drug-resistant tuberculosis: Epidemiology and management

Clinical Epidemiology

Volumn 6, Issue 1, 2014, Pages 111-118

  Matteelli, Alberto ^a   Roggi, Alberto ^a   Carvalho, Anna C C ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Control; Diagnosis; Epidemiology; Treatment; XDR TB

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CARBAPENEM; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; TERIZIDONE; THIORIDAZINE;

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; BONE MARROW SUPPRESSION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE TRANSMISSION; DRUG MEGADOSE; DRUG TOLERABILITY; EARLY DIAGNOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; INAPPROPRIATE PRESCRIBING; INCIDENCE; INFECTION CONTROL; INFECTION RISK; LUNG RESECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROPATHY; OPTIMAL DRUG DOSE; PATIENT ATTITUDE; PREVALENCE; RELAPSE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS CONTROL; UNSPECIFIED SIDE EFFECT;

EID: 84898751124     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S35839     Document Type: Review

References (70)

1. Caminero JA, Torres A. Controversial topics in tuberculosis. Eur Respir J. 2004;24:895-896.
2. Grzybowski S, Enarson DA. [Results in pulmonary tuberculosis patients under various treatment program conditions]. Bull Int Union Tuberc. 1978;53:70-75. French.
3. World Health Organization. Global Tuberculosis Report 2013. Geneva: WHO; 2013. Available from: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf. Accessed December 2, 2013.
4. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet. 2012;379:1902-1913.
5. Boehme CC, Nabeta P, Hillemann D. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005-1015.
6. World Health Organization. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. Geneva: WHO; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf. Accessed October 25, 2013.
7. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis. 2012;16:1005-1014.
8. [No authors listed]. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. Br Med J. 1948;2:769-782.
9. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis. 2012;205 (Suppl 2):S228-S240.
10. Zumla A, George A, Sharma V, Herbert N, Baroness Masham of Ilton. WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet. Epub October 22, 2013.
11. World Health Organization. Definitions and Reporting Framework for Tuberculosis-2013 Revision. Geneva: WHO; 2013.
12. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-305.
13. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J. 2007;30:623-626.
14. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill. 2007;12:E070517.1.
15. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drugresistant tuberculosis or totally drug-resistant strains in Iran. Chest. 2009;136:420-425.
16. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drugresistant tuberculosis in India. Clin Infect Dis. 2012;54:579-581.
17. Cegielski P, Nunn P, Kurbatova EV, et al. Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis. 2012;18:e2.
18. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-1580.
19. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-1807.
20. Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, der Walt ML. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr. 2011;57:146-152.
21. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013;13:529-539.
22. Migliori GB, Sotgiu G, D'Ambrosio l, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J. 2012;39:619-635.
23. Bonilla CA, Crossa A, Jave HO, et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One. 2008;3:e2957.
24. Shin SS, Keshavjee S, Gelmanova IY, et al. Development of extensively drug resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010;182:426-432.
25. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380:1406-1417.
26. Skrahina A, Hurevich H, Zalutskaya A, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91:36-45.
27. Basu S, Friedland GH, Medlock J, et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci U S A. 2009;106:7672-7677.
28. World Health Organization. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva: WHO; 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf. Accessed October 25, 2013.
29. Sotgiu G, D'Ambrosio L, Centis R, et al. TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel? Eur Respir J. 2011;38:1221-1223.
30. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312:1944-1946.
31. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;12:1456-1466.
32. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis. 2012;205 (Suppl 2):S147-S158.
33. World Health Organization. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva: WHO; 2008. Available from: http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf. Accessed October 25, 2013.
34. O'Grady J, Maeurer M, Mwabab P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med. 2011;17:134-141.
35. Glaziou P, Falzon D, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Semin Respir Crit Med. 2013;34:3-16.
36. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006;368:2142-2154.
37. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva: WHO; 2011.
38. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621-629.
39. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33:871-881.
40. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51:6-14.
41. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J. 2013;42:156-168.
42. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur Respir J. 2013;42:169-179.
43. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PloS Med. 2012;9:e1001300.
44. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359:563-574.
45. Orenstein EW, Basu S, Shah NS, et al. Treatment outcome among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-161.
46. Johnston JC, Shahidi NC, Sadatsafavi M, FitzGerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4:e6914.
47. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516-528.
48. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40: 1430-1442.
49. Lee M, Lee J, Carrol MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367: 1508-1518.
50. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2013;68:284-293.
51. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem/clavulanate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur Respir J. 2013;41:1386-1392.
52. Amaral L. Thioridazine: an old neuroleptic effective against totally drug resistant tuberculosis. Acta Med Port. 2012;25:118-121.
53. Abbate E, Vescovo M, Natiello M, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother. 2012;67:473-477.
54. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012;205 Suppl 2:S241-S249.
55. World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: WHO; 2013.
56. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397-2405.
57. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56:3271-3276.
58. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrugresistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151-2160.
59. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J. 2013;41:1393-1400.
60. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012;380:986-993.
61. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV infected patients with multidrugresistant tuberculosis. Clin Infect Dis. 2007;45:1290-1295.
62. Eker B, Ortmann J, Migliori GB, et al. Multidrugand extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis. 2008;14: 1700-1706.
63. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372:1403-1409.
64. Pontali E, Matteelli A, D'Ambrosio L, Centis R, Migliori GB. Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. Expert Rev Anti Infect Ther. 2012;10:1109-1115.
65. Xu HB, Jiang RH, Li L. Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1687-1695.
66. Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis. 2012;12:157-166.
67. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-662.
68. Bloland K, Viiklepp P, Gudmundsson LJ, Altraia A. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16:12128-12133.
69. Rieder HL, Cauthen GM, Comstock GW, Snider DE. Epidemiology of tuberculosis in the United States. Epidemiol Rev. 1989;11:79-98.
70. Liu CH, Li L, Chen Z, etal. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One. 2011;6:e19399.